Swiss real-world study to assess Saxenda® weight loss and treatment patterns in adults with obesity or overweight
Background
Obesity and overweight are chronic conditions associated with significant health risks, including type 2 diabetes, cardiovascular disease, and certain cancers. While lifestyle interventions are foundational, pharmacological treatments are often necessary for sustained weight management. Liraglutide (Saxenda®), a GLP-1 receptor agonist, is an approved option that promotes satiety and reduces food intake. However, real-world data on its effectiveness and treatment patterns outside of controlled clinical trials are crucial to understand its practical impact and optimize patient care.
Study Design
This was a single-center, non-interventional chart-review study conducted in Switzerland, collecting data from available medical records. Adult patients with obesity or overweight who were prescribed Saxenda® by their treating physician independently of the study were included. The study aimed to assess weight loss and treatment patterns over approximately 4 months of data collection. No additional activities or interventions were performed on participants, as data was retrospectively extracted from routine clinical practice records.
Results
This research record describes the design of an observational study; therefore, no specific findings or numerical results are available at this time. The study aims to collect real-world data on Saxenda® use and its associated weight loss outcomes and treatment adherence patterns in routine clinical practice. Future publications from this study are expected to provide insights into the effectiveness and practical application of liraglutide in a Swiss adult population.
Why It Matters
Understanding Saxenda®'s performance in real-world settings is critical for clinicians and patients, as controlled trials may not fully reflect diverse patient populations or adherence challenges. This chart-review study will provide valuable insights into actual weight loss achieved and how patients adhere to treatment in routine clinical practice. Real-world evidence can inform prescribing practices and patient counseling, potentially highlighting factors that influence treatment success or discontinuation. While not a new protocol, the data could refine expectations for liraglutide efficacy and persistence outside of highly controlled environments.